# Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

> clinical trial · VERIFIED · 2026-08-11

Status: NOT_YET_RECRUITING · Sponsor: Nuvation Bio Inc. · Condition: Grade 2 IDH1-mutant Glioma

- Company: Nuvation Bio Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07703436

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.